William Sera
Family · Albuquerque, NMNPI 1679747646
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 93.1% of the total across 198 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 22 manufacturers, the largest accounting for just 19.3% — the pattern of someone who eats at a lot of different presentations. Among family clinicians in NM with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 198 payments — averaging $22.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$841
- Boehringer Ingelheim$531
- Novo Nordisk$454
- Bayer$426
- Dexcom, Inc.$385
- Tandem Diabetes Care, Inc.$336
- plus $1K from 16 others
What the payments were for
- Speaking & faculty fees$3007%
- Food & beverage$4,06093%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 43 | $841 |
| Boehringer Ingelheim | 22 | $531 |
| Novo Nordisk | 25 | $454 |
| Bayer | 22 | $426 |
| Dexcom, Inc. | 19 | $385 |
| Tandem Diabetes Care, Inc. | 3 | $336 |
| Amgen(2 entities) | 11 | $291 |
| Xeris Pharmaceuticals, Inc. | 15 | $232 |
| Radius Health, Inc. | 3 | $174 |
| Recordati_rare_diseases_inc. | 7 | $158 |
| Acella Pharmaceuticals, LLC | 6 | $108 |
| AstraZeneca(2 entities) | 4 | $87 |
| Insulet Corporation | 3 | $62 |
| Corcept Therapeutics | 3 | $59 |
| Sanofi-aventis U.S. LLC | 3 | $49 |
| Medtronic | 2 | $35 |
| Avion Pharmaceuticals | 2 | $30 |
| Abbott | 1 | $23 |
| Amneal Pharmaceuticals LLC | 1 | $23 |
| AbbVie | 1 | $20 |
| Ascendis Pharma Endocrinology Inc | 1 | $18 |
| Averitas Pharma Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,360 in reported general payments places this provider in the 95th percentile of 1,080 family providers in New Mexico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 126 | $155,951 |
| JardianceEmpagliflozin | 90 | $85,081 |
| FarxigaDapagliflozin Propanediol | 73 | $75,281 |
| MounjaroTirzepatide | 62 | $66,030 |
| TrulicityDulaglutide | 54 | $54,301 |
| Tresiba Flextouch U-200Insulin Degludec | 37 | $42,610 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 24 | $29,041 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 19 | $21,497 |
| RybelsusSemaglutide | 14 | $20,124 |
| KerendiaFinerenone | 24 | $18,651 |
| JanuviaSitagliptin Phosphate | 28 | $17,079 |
| Tresiba Flextouch U-100Insulin Degludec | 24 | $14,411 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 36 | $11,835 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 94 | $11,508 |
| InvokanaCanagliflozin | 15 | $10,509 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $454 | $176,075140 claims |
| Lilly USA, LLCMounjaro, Trulicity | $841 | $120,331116 claims |
| Boehringer IngelheimJardiance | $531 | $85,08190 claims |
| AstraZenecaFarxiga | $87 | $75,28173 claims |
| BayerKerendia | $426 | $18,65124 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $23 | $1,957191 claims |
| Acella Pharmaceuticals, LLCNp Thyroid | $108 | $1,87550 claims |
| AbbVieArmour Thyroid | $20 | $1,66723 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,080 family providers in New Mexico.
Other family in Albuquerque
- Barbara FranklinAlbuquerque$28K
- Melanie DuranAlbuquerque$15K
- Irasema LlewellynAlbuquerque$14K
- Charles GallegosAlbuquerque$10K
- Marlyn NewbyAlbuquerque$9K
- Annmarie FoleyAlbuquerque$8K
- Aimee CasarezAlbuquerque$7K
- Rita SuharliAlbuquerque$6K
- Matthew TotterAlbuquerque$6K
- Roberta ChampouillonAlbuquerque$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.